Advertisement

Topics

Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Retinal Diseases and Changes Name to IVERIC bio

12:09 EDT 16 Apr 2019 | Speciality Pharma Journal

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the Company is changing its name to IVERIC bio, Inc. In conjunction with the corporate name change, the Company will trade …

Original Article: Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Retinal Diseases and Changes Name to IVERIC bio

NEXT ARTICLE

More From BioPortfolio on "Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Retinal Diseases and Changes Name to IVERIC bio"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...